TAD after NAC for node-positive breast cancer

Less invasive axillary surgery after neoadjuvant chemotherapy for node-positive primary breast cancer : A multicenter prospective study - Less invasive axillary surgery after neoadjuvant chemotherapy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1032210236

Enrollment

112

Registered

2021-08-12

Start date

2021-08-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

node-positive primary breast cancer at dianosis who receive neoadjuvant chemotherapy Breast Neoplasm

Interventions

removal of at least 3 clipped nodes and sentinel nodes

D019060

Minimally Invasive Surgical Procedures

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Estrogen receptor negative invasive ductal carcinoma 2. Axillary lymphnode metastasis confirmed by biopsy or cytology at diagnosis 3. Upto 3 axillary lymphnode metastases on ultrasound or CT at diagnosis 4. A clinical T1 or T2 invasive ductal carcinoma 5. Candidate for anthracycline and taxane-based neoadjuvant chemotherapy 6. 20 year or older 7. Written patient Informed consent 8. Performance status: ECOG 0 -1 9. Maintained organ function

Exclusion criteria

Exclusion criteria: 1. Stage IV disease with distant metastasis 2. Pregnancy 3. Inflammatory breast cancer 4. Invasive lobular or invasive micropapillary carcinoma 5.bilateral breast cancer 6. Metal allergy 7. Prior history of axillary surgery or radiation therapy on axillary field 8. Active infection disease 9. Inability to join the study due to mental status 10. BMI: Body mass index 35 or higher 11. Other conditions regarded as intoleratable for the study

Design outcomes

Primary

Measure	Time frame
3 year locoregional recurrence-free survival	—

Secondary

Measure	Time frame
negative predictive value of node negative, 3 year regional recurrence-free survival, 3 year distant disease-free survival, Complication rate	—

Contacts

Public ContactNaoki Hayashi

St. Luke's International University, St. Luke's International Hospital

naokiha@luke.ac.jp+81-3-3541-5151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026